# TCHAIKAPHARMA HIGH QUALITY MEDICINES INC. INTERIM REPORT AS OF THE 31st OF MARCH 2017

#### INTERIM STATEMENT OF FINANCIAL STATUS AS OF 31.03.2017

	Appendices	31.03.2017	31.12.2016
ASSETS		BGN'000	BGN'000
Non-current assets			
Property, plant and equipment	1	26 069	25 888
Intangible assets	2	3 728	3 644
Investments with minority interest	3	1	1
Trade receivables	4	6 080	6 025
Total non-current assets		35 878	35 558
Current assets			
Inventories	5	5 106	5 082
Trade and other receivables	5	51 823	50 373
Financial assets with maturity	5	8	24
Cash and cash equivalents	6	40	50
Total current assets		56 977	55 529
Total assets		92 855	91 087
LIABILITIES			
Equity capital			
Registered capital	7	56 600	56 600
-	8	7 810	7 810
Statutory reserves	8	11 441	
Undistributed profit  Total	8	75 851	8 585 <b>72 995</b>
Non-current liabilities			
Long-term loans	9	915	1 015
Deferred tax liabilities	10	1 284	1 284
Liabilities to employees on retirement	10	67	67
Total non-current liabilities		2 266	2 366
Current liabilities			
Trade and other liabilities	11	3 121	2 909
Short-term loans	9	10 169	11 349
Current part of long-term loans	9	748	869
Current corporate tax	11	71	55
Other tax payables	11	629	544
Total current liabilities		14 738	15 726
Total liabilities		17 004	18 092
Total equity capital and liabilities		92 855	91 087
Draft date: 04.04.2017			
Sofia Prepared by:		Director:	
/ B. Ivanov /			/B. Georgiev/

# TCHAIKAPHARMA HIGH QUALITY MEDICINES INC. INTERIM REPORT AS OF THE 31st OF MARCH 2017

## INTERIM STATEMENT OF COMPREHENSIVE INCOME AS OF 31.03.2017

	Appendices	31.03.2017 BGN'000	31.03.2016 BGN'000
Revenues	12	7 644	8 351
Other income	12		
Total income		7 644	8 351
Balance value of assets sold	13	(164)	(1 307)
Changes in inventories of products and work in			
progress	13	374	294
Cost for materials and services	13	(3 051)	(2 681)
Employee costs	13	(782)	(742)
Amortization costs	13	(729)	(867)
Other expenses	13	(26)	(111)
Financial income	14	7	36
Financial expenses	14	(100)	(137)
Total expenses		(4 471)	(5 515)
Profit before taxation		3 173	2 836
Corporate tax cost	15	(317)	(284)
Profit/Loss for the period		2 856	2 552
Other comprehensive income for the period			
Total comprehensive income for the period			
Income per share / in BGN per 1 share /	16	0.05	0.05

Draft date: (	04.04.2017	
Sofia	Prepared by:	Director:
	/B. Ivanov/	/B. Georgiev/

# TCHAIKAPHARMA HIGH QUALITY MEDICINES INC. INTERIM REPORT AS OF THE 31st OF MARCH 2017

### INTERIM CASH FLOW REPORT AS OF 31.03.2017

	31.03.2017	31.03.2016
Cash flow from operating activities	BGN'000	BGN'000
Revenues from produce, goods and services	7 873	6 496
Payments to suppliers of materials, goods and services	(3 222)	(2 542)
Payments to personnel	(709)	(713)
Payments of interest and dividends	(3)	(3)
Corporate tax payments	(301)	(346)
Other revenues/payments	(1 342)	(1 563)
Net cash flow	2 296	1 329
Cash flow form investment activities		
Payments for non-current assets aquired	(824)	(361)
Net cash flow	(824)	(361)
Cash flow from financial activities		
Revenues from loans received		
Payments for loans received	(1 174)	(264)
Payment of interest, dividends	(68)	(80)
Payment for finance lease	(240)	(596)
Other revenues/payments		
Net cash flow	(1 482)	(940)
Change of each and each equivalents	(10)	28
Change of cash and cash equivalents	50	40
Cash and cash equivalents at the beginning of the period	40	
Cash and cash equivalents at the end of the period	40	68

Draft date: 04	1.04.2017	
Sofia	Prepared by:	Director:
	/B. Ivanov/	/B. Georgiev /

# TCHAIKAPHARMA HIGH QUALITY MEDICINES INC. INTERIM REPORT AS OF THE 31st OF MARCH 2017

### INTERIM STATEMENT OF CHANGES IN EQUITY AS OF 31.03.2017

	Appendices	Registered capital <b>BGN'000</b>	Revaluation reserves <b>BGN'000</b>	Other reserves <b>BGN'000</b>	Undistributed profit/loss <b>BGN'000</b>	Total equity <b>BGN'000</b>
Balance as of 01.01.2016	7,8	49 600	2 711	3 881	7 780	63 972
Profit/loss for the period Other comprehensive income	8		438		8 585	8 585 438
Including from tax effect of the revaluation of property, plant and equipment Total comprehensive income			(50) 438		8 585	(50) <b>9 023</b>
income			730		0 303	7 023
Issue of shares by the owners Accrued dividends		7 000			(7 000)	
Accrued tantiemmes Transferred to profit reserves Total recognized amount of income and expenses for	8			780	(780)	
the period	<b>-</b>	7 000		780	(7 780)	
Balance as of 31.12.2016	7,8	56 600	3 149	4 661	8 585	72 995
Balance as of 01.01.2017	7,8	56 600	3 149	4 661	8 585	72 995
Profit/loss for the period Other comprehensive income	8				2 856	2 856
Total comprehensive income					2 856	2 856
Issue of shares by the owners Accrued dividends Accrued tantiemmes Transferred to profit reserves Total recognized amount of income and expenses for the period	8					
Balance as of 31.03.2017	7,8	56 600	3 149	4 661	11 441	75 851
	·	2000				

Draft date: 04.04.2017

Sofia